What do new lytics add to t-PA?

American Heart Journal

Volumn 138, Issue 2 II, 1999, Pages

  Van de Werf, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ALTEPLASE DERIVATIVE; ALTEPLASE TNK; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; SARUPLASE; STREPTOKINASE; UNCLASSIFIED DRUG;

BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION;

EID: 0032813916     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70330-3     Document Type: Article

References (33)

1. White HD, Van de Werf F. Thrombolysis for acute myocardial infarction. Circulation 1998;97:1632-46.
2. Browne MJ, Carey JE, Chapmann CG, et al. A tissue-type plasminogen activator mutant with prolonged clearance in vivo: effect of removal of the growth factor domain. J Biol Chem 1988;263:1599-602.
3. Hotchkiss A, Refino CJ, Leonard CK, et al. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 1988;60:255-61.
4. Madison EL, Goldsmith EJ, Gerard RD, et al. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A 1990;87:3530-3.
5. Collen D, Lijnen HR, Gold HK. Towards better thrombolytic therapy. Prog Cardiovasc Dis 1991;34:101-12.
6. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995;346:329-36.
7. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)-III Investigators: a comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
8. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-32.
9. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;72:518-24.
10. den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. Circulation 1998;98:2117-25.
11. Bennett WF, Paoni NF, Keyt BA, et al. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991;266:5191-201.
12. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994;91(9):3670-4.
13. Cannon CP, McCabe CH, Gibson MC, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)-10A dose-ranging trial. Circulation 1997;95:351-6.
14. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. Ann Intern Med 1991;115:256-65.
15. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-9.
16. Modi NB, Eppler S, Breed J, et al. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-t-PA, in patients with acute myocardial infarction. Thromb Haemost 1998;79:134-9.
17. Cannon CP, Gibson MC, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI-10B trial. Circulation 1998;98:2805-14.
18. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK-t-PA in acute myocardial infarction: the ASSENT-I trial. Am Heart J 1999, in press.
19. Giugliano RP, Cannon CP, McCabe CH, et al. Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: results from TIMI-10B and ASSENT-I. Circulation 1997;96(suppl I):I-535.
20. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1998;1:863-8.
21. Bär FW, Meyer J, Vermeer F, et al. Combination of saruplase and alteplase in acute myocardial infarction: the Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997;79:727-32.
22. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 1998;31:487-93.
23. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 1994;84:680-6.
24. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-9.
25. Vanderschueren S, Dens J, Kerdsinchai P, et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997;134:213-9.
26. Pislaru S, Pislaru C, Zhu X, et al. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as adjunct to coronary thrombolysis. Thromb Haemost 1998;79:1130-5.
27. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
28. Antman EM, for the TIMI-9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI)-9B trial. Circulation 1996;94:911-21.
29. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. J Am Coll Cardiol 1998;31:1493-8.
30. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-61.
31. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-9.
32. Antman EM, Giugliano RP, Gibson MC, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the TIMI-14 trial. Circulation, in press.
33. Ohman ME, Lincoff MA, Bode C, et al. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial. Circulation 1998;98(suppl I):I-504.